NEURAXIS, INC. Net Change in Cash
NEURAXIS, INC. (NRXS) reported Net Change in Cash of $3.36 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect · last filed 2026-08-11
- NEURAXIS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2026-03-31 was $2.11M.
- NEURAXIS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2025-03-31 was -$1.69M, a 53091.85% decline year-over-year.
- NEURAXIS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2024-03-31 was $3.19K.
- NEURAXIS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for the quarter ending 2023-03-31 was -$208.24K.
- NEURAXIS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2025 was $1.27M, a 64.95% decline from fiscal 2024.
- NEURAXIS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2024 was $3.62M.
- NEURAXIS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2023 was -$175.14K.
- NEURAXIS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), including exchange rate effect for fiscal 2022 was -$67.16K.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.36M 10-Q · filed 2026-08-11 | |||
| 2026-03-31 | $2.11M 10-Q · filed 2026-05-12 | |||
| 2025-12-31 | $1.27M 10-K · filed 2026-03-19 | |||
| 2025-09-30 | $680.24K 10-Q · filed 2025-11-10 | |||
| 2025-06-30 | $2.29M 10-Q · filed 2026-08-11 | |||
| 2025-03-31 | -$1.69M 10-Q · filed 2026-05-12 | |||
| 2024-12-31 | $3.62M 10-K · filed 2026-03-19 | |||
| 2024-09-30 | $182.32K 10-Q · filed 2025-11-10 | |||
| 2024-06-30 | $1.69M 10-Q · filed 2025-08-12 | |||
| 2024-03-31 | $3.19K 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | -$175.14K 10-K · filed 2025-03-20 | |||
| 2023-09-30 | $507.55K 10-Q · filed 2024-11-12 | |||
| 2023-06-30 | -$202.26K 10-Q · filed 2024-08-09 | |||
| 2023-03-31 | -$208.24K 10-Q · filed 2024-05-20 | |||
| 2022-12-31 | -$67.16K 10-K · filed 2024-04-16 | |||
| 2022-09-30 | -$313.04K 10-Q · filed 2023-11-20 | |||
| 2022-06-30 | -$247.21K 10-Q · filed 2023-09-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nexalin Technology, Inc. (NXL) | United States | $0.094B | |
| electroCore, Inc. (ECOR) | United States | $0.102B | |
| Streamex Corp. (STEX) | United States | $0.089B | -0.19 |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| Outset Medical, Inc. (OM) | United States | $0.059B | -1.09 |
| PRECISION OPTICS CORPORATION, INC. (POCI) | United States | $0.052B | |
| QT IMAGING HOLDINGS, INC. (QTI) | United States | $0.037B | |
| EDAP TMS SA (FOCL) | $0.171B | ||
| IRIDEX CORP (IRIX) | United States | $0.011B |